2025 Is A Year Of Firsts As Biosimilars Build Momentum In US

Ustekinumab, Denosumab, Eculizumab And Natalizumab Rivals Launch

Dec 19 2025

• By Dave Wallace

More molecules fell to US biosimilar competition for the first time in 2025 (Shutterstock)

More from Generics Bulletin Perspectives

More from Generics Bulletin